REGENXBIO CMO sells 15,309 shares in plan trade

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 15,309 shares of common stock on May 11, 2026 at a weighted average price of $11.02 per share.

Rhea-AI Filing Summary

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 15,309 shares of common stock on May 11, 2026 at a weighted average price of $11.02 per share. The transaction was executed under a Rule 10b5-1 trading plan, and he continues to hold 232,617 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 15,309 shares

Net Sell 1 txn

Insider PAKOLA STEVE

Role Chief Medical Officer

Sold 15,309 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,309	$11.02	$169K

Holdings After Transaction: Common Stock — 232,617 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
2. F2. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 15,309 shares Weighted average sale price: $11.02 per share Post-transaction holdings: 232,617 shares +3 more

6 metrics

Shares sold 15,309 shares Open-market sale on May 11, 2026

Weighted average sale price $11.02 per share Common stock sale on May 11, 2026

Post-transaction holdings 232,617 shares Shares directly held after sale

Transaction code S (sale) Open-market or private transaction code on Form 4

Trading plan Rule 10b5-1 Sale effected pursuant to a trading plan

Price range $11.00–$11.10 per share Individual trades’ execution range noted in footnote

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did REGENXBIO (RGNX) report for Steve Pakola?

REGENXBIO reported that Chief Medical Officer Steve Pakola sold 15,309 shares of common stock. The sale occurred on May 11, 2026, as an open-market transaction executed under a Rule 10b5-1 trading plan, according to the Form 4 filing details.

At what price did REGENXBIO (RGNX) CMO Steve Pakola sell his shares?

Steve Pakola sold his 15,309 REGENXBIO shares at a weighted average price of $11.02 per share. Footnotes state individual trades were executed between $11.00 and $11.10, with the reported figure reflecting the overall weighted average sale price.

How many REGENXBIO (RGNX) shares does Steve Pakola hold after the sale?

After the reported sale, Steve Pakola directly holds 232,617 shares of REGENXBIO common stock. This post-transaction holding figure comes from the Form 4 and shows he retains a substantial equity position following the open-market sale under the trading plan.

Was the REGENXBIO (RGNX) insider sale made under a Rule 10b5-1 plan?

Yes, the filing notes the sale was executed under a Rule 10b5-1 trading plan. Such plans allow pre-arranged trades according to preset instructions, indicating this transaction was scheduled in advance rather than being a spontaneous market-timing decision by the executive.

What type of transaction did REGENXBIO (RGNX) report for its CMO on Form 4?

The Form 4 describes the transaction as an open-market sale of common stock. It is coded as a “S” transaction, representing a sale in the open market or a private transaction, with pricing details and trading range disclosed in the accompanying footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 05:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAKOLA STEVE

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		15,309	D	$11.02(2)	232,617	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.

2. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)